Acurx Pharmaceuticals, Inc.ACXP
...Loading ACXP Peers...
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
4 Employees
CEO : Mr. David P. Luci CPA, Esq., J.D.
Address : 259 Liberty Avenue, Staten Island,NY, US, - 10305,
Key Excutives | Designation |
---|---|
Mr. David P. Luci CPA, Esq., J.D. | Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director |
Mr. Robert G. Shawah CPA, CPA | Co-Founder & Chief Financial Officer |
Mr. Robert J. DeLuccia | Co-Founder & Executive Chairman |